Central Nervous System

Bristol Myers Squibb reports data from Phase III multiple sclerosis trial

Bristol Myers Squibb (BMS) has unveiled the latest data from the Phase III DAYBREAK clinical trial, highlighting the long-term efficacy…

Another setback for Minerva’s schizophrenia treatment roluperidone

On February 27, Minerva Neurosciences announced that it received a complete response letter (CRL) from the FDA regarding the company’s…

Comorbidities associated with ADHD present an opportunity for pipeline products

Attention deficit hyperactivity disorder (ADHD) is a clinically heterogeneous disorder, with published research often putting comorbidity estimates at between 60%–80%.…

Minerva hit with FDA rejection for schizophrenia symptom drug

A potential landmark year for schizophrenia treatments has got off to a rocky start, after the US Food and Drug…

IRLAB dosing patients in Phase IIb Parkinson’s disease trial

Swedish company IRLAB Therapeutics is dosing patients in its ongoing Phase IIb trial of its pipeline candidate pirepemat in Parkinson’s disease…

Encoded receives UK approval for Dravet syndrome therapy trial

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Encoded Therapeutics’ clinical trial authorisation application for the Phase…

AriBio receives MHRA approval to commence Phase III Alzheimer’s trial

AriBio has announced the receipt of a Notice of Acceptance from the Medicines and Healthcare products Regulatory Agency (MHRA) in…

Olatec to launch Phase II trial of dapansutrile for Parkinson’s disease

Olatec Therapeutics has received a grant to commence a Phase II clinical trial of dapansutrile to slow down or stop…

Sanofi and Denali’s ALS therapy misses primary endpoint in Phase II

Sanofi and Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) therapy, SAR443820/DNL788, failed to meet its primary endpoint in the Phase II…

Cellenkos’ ALS cell therapy clinical trial progresses to next phase

Cellenkos has received approval to advance to the second cohort of patients in its clinical trial of neurotrophic T regulatory…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close